N-Acetyl Selank Amidate
Research OnlyA modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.
NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate · NASA
Preclinical evidence only
- Preclinical
- 100%
- Clinical
- 0%
Based on 2 cited sources
community-reported · not clinically demonstrated · very-low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 2 (1A 0, 1B 0, 1C 0, 1D 2, 1E 0): zero studies exist on N-Acetyl Selank Amidate itself — the dossier explicitly states no direct research — so all human-evidence elements score 0; only a small indirectness credit (1D) for parent-compound Selank data, which is a different molecule. Mechanism 22 (2A 10, 2B 8, 2C 0, 2D 4): target inferred from the shared Selank core sequence with no binding data on this modification; enkephalinase inhibition (15344652) and BDNF (18841804) characterized for the parent only, no dose-response for this compound. Plausibility 59 (3A 15, 3B 18, 3C 14, 3D 12): anxiolytic claim plausible but hinges on the unproven assumption that N-acetylation/C-amidation preserves activity; coheres with Selank biology, same-class analogy from the parent's GAD RCT (18454096), tightly scoped claim. Global Coverage 12 (4A 3, 4B 4, 4C 5, 4D 0): zero independent research on this molecule; parent literature concentrated in one Russian group; no governance review of this modification. Community Experience 40 (5A 10, 5B 10, 5C 12, 5D 8): niche but persistent nootropic-community use, broadly consistent "longer duration than standard selank" reports, no recurring serious adverse signal over limited exposure. Overall 25 → preliminary. Effectiveness basis community-reported (capped at 50, very-low confidence): no human efficacy data on this compound; CR1 10 + CR2 10 + CR3 5 = 25 from consistent but single-community anecdote.
The proposed mechanisms of N-Acetyl Selank Amidate are extrapolated entirely from the parent compound Selank. No direct research exists on this specific modification.
How It Works (Simplified)
N-Acetyl Selank Amidate is theorized to work through the same pathways as Selank, with potentially enhanced stability:
Proposed to enhance GABA-A receptor sensitivity, promoting inhibitory neurotransmission and anxiolytic effects (based on Selank data).
Theorized to inhibit enkephalinase, preserving endogenous opioid peptides involved in mood and stress response.
Proposed to upregulate brain-derived neurotrophic factor, potentially supporting neuroplasticity and cognitive function.
N-acetylation and C-amidation theoretically protect against aminopeptidase and carboxypeptidase degradation, extending half-life.
Key Research: No direct studies exist on N-Acetyl Selank Amidate. Parent compound data from Zozulia AA et al. (2008) demonstrated Selank anxiolytic effects. PMID:18454096
Important Limitations
- Zero published studies on N-Acetyl Selank Amidate specifically
- All mechanisms extrapolated from parent compound Selank
- Modifications may alter or eliminate biological activity
- Human pharmacokinetics completely unknown
Reported positives
- Longer-lasting effects than standard selank reported
- Enhanced bioavailability from modified form
- Anxiolytic effects without cognitive impairment
- Stable nasal spray formulation
Reported negatives
- More expensive than standard selank
- Limited availability compared to standard form
- Long-term safety data lacking
- Subtle effects may not meet expectations
“Preferred by some over standard selank for longer duration. Niche following in nootropic communities.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on parent compound data: Users report initial anxiolytic effects within days. No pharmacokinetic data exists for NA-Selank-Amidate to confirm onset timing.
PMID:18454096Theoretical continued GABAergic modulation and enkephalin protection. Parent compound studies suggest sustained anxiolytic effects with continued use.
PMID:18454096Long-term effects completely unknown. No studies on extended use of either Selank or NA-Selank-Amidate beyond short-term trials.
PMID:18454096No data available. Human pharmacokinetics, tolerance development, and optimal treatment duration are completely unknown for this modification.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Selank
SynergisticParent compound with identical core sequence. NA-Selank-Amidate may have improved stability but shares the same mechanisms. No studies on combining the two forms.
Na-Semax-Amidate
CompatibleBoth are modified Russian nootropic peptides targeting different pathways. Semax focuses on BDNF/NGF while Selank emphasizes GABAergic modulation. Commonly stacked in nootropic protocols.
Semax
CompatibleDifferent mechanisms of action. Semax targets neurotrophic factors while Selank focuses on anxiolytic pathways. No known contraindications.
Dihexa
CautionBoth target cognitive pathways through different mechanisms. Limited safety data on combination. Exercise caution due to lack of interaction studies.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare N-Acetyl Selank Amidate
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.